Brazil RSV Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Brazil · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$107.0 MnPlaceholder estimate
Estimate 2025$120.7 Mn2.8% of the global market
Projected 2034$357.0 Mn 195.7%Adds $236.2 Mn over 9 forecast years
CAGR 2025–203412.8%Faster than 66% of 180 Pharmaceuticals markets here
Key players5
Brazil is 2.75% of the global market.
In Latin America, the largest is Brazil (this report) at $120.7 Mn.
Fastest growing: Brazil (this report) at 12.8% a year.
Brazil ranks 1st of 3 by size in Latin America.
Market size projection
Brazil
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$236.2 Mn total, 2026–2034
Year-by-year market size, 2024–2034
RSV Vaccines Market market size by year, Brazil
Year
Market size
Change that year
Since 2025
2024 (estimate)
$107.0 Mn
—
—
2025 (base)
$120.7 Mn
+$13.7 Mn
—
2026 (forecast)
$136.2 Mn
+$15.5 Mn
+12.8%
2027 (forecast)
$153.6 Mn
+$17.4 Mn
+27.2%
2028 (forecast)
$173.3 Mn
+$19.7 Mn
+43.5%
2029 (forecast)
$195.5 Mn
+$22.2 Mn
+61.9%
2030 (forecast)
$220.5 Mn
+$25.0 Mn
+82.6%
2031 (forecast)
$248.7 Mn
+$28.2 Mn
+106%
2032 (forecast)
$280.6 Mn
+$31.8 Mn
+132.4%
2033 (forecast)
$316.5 Mn
+$35.9 Mn
+162.1%
2034 (forecast)
$357.0 Mn
+$40.5 Mn
+195.7%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
1 in BrazilSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Brazil RSV Vaccines Market Analysis Executive Summary
RSV vaccines protect older adults, pregnant women (for their babies) and infants against respiratory syncytial virus, a common cause of serious chest infections.
Key segments of the RSV Vaccines market include product (Older Adult Vaccines, Maternal Vaccines and Infant Monoclonal Antibodies) and age (Infants, Older Adults and Pregnant Women).
Brazil RSV Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Brazil RSV Vaccines Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the RSV Vaccines market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the RSV Vaccines market.
Competitive Landscape for RSV Vaccines Market in Brazil
The RSV Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for RSV Vaccines Market in Brazil
RSV Vaccines in Brazil: rules, payment and research
Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale.[1] The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds.[2] ClinicalTrials.gov lists 1 study on RSV Vaccines that is recruiting, active or about to start in Brazil.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RSV Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Brazil.
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in RSV Vaccines right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
RSV Vaccines in context
Brazil compared
Health spending per person: 1,010 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 4 countries we cover in Latin America.[1]
Doctors: 2.36 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 2nd highest of the 4 countries we cover in Latin America.[2]
People aged 65 and over: 11.5% of people (2025). World: 10.4% of people (2025). Highest of the 4 countries we cover in Latin America.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
Placeholder estimate: about $120.7 Mn in 2025, rising to about $357.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the RSV Vaccines market in Brazil growing?
Placeholder estimate: about 12.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the RSV Vaccines market report cover?
The report splits the market by product (Older Adult Vaccines, Maternal Vaccines, Infant Monoclonal Antibodies), age (Infants, Older Adults, Pregnant Women) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the RSV Vaccines market?
Key players include GSK PLC, Pfizer Inc., Moderna, Sanofi and AstraZeneca.
What is driving the RSV Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.
Who regulates RSV Vaccines in Brazil?
Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale. Source: ANVISA. Checked 14 Nov 2026.
How is healthcare paid for in Brazil?
The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds. Source: CONITEC. Checked 14 Nov 2026.
How many clinical trials on RSV Vaccines are running in Brazil?
1 study is recruiting, active or about to start in Brazil, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
How much research is published on RSV Vaccines?
PubMed lists 397 papers on RSV Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Brazil 
US
Canada
China
Japan
Germany
France
UK
Italy
Spain
India
Ecuador
Saudi Arabia
Mexico
New Zealand
Australia
Russia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
Aurobindo Pharma
Merck & Co., Inc.